

## **Materials and Methods**

### *Construction of donor DNA plasmids*

Modified polyA trap vector for targeted insertion near transcriptional termination sites was designed as follows: CMV promoter-puromycin coding sequence-LoxP-donor sgRNA target site-2×MS2 tags -LoxP, was synthesized by Genescript and inserted into vector pUC57-Simple with NdeI and SapI. Here the donor sgRNA site was selected as described previously (Sequence: GGCCAGTACCCAAAAAGCGGGG)(Schmid-Burgk et al., 2016). 24×MS2 tags were added just after donor sgRNA site to obtain puromycin-selection vector with 24×MS2 tags for RNA-immunoprecipitation (RNA-IP) analysis.

Modified promoter trap vector for targeted insertion near transcriptional start sites was designed as follows: LoxP-donor sgRNA target site- 2×MS2 tags -LoxP-puromycin coding sequence-polyA, was synthesized by Genescript and inserted into vector pUC57-Simple with NdeI and SapI. Donor sgRNA site is the same as modified polyA trap vector.

### *Construction of MS2-EGFP fusion plasmid*

MS2-EGFP fusion plasmid was constructed as follows: the coding sequence of MS2-binding protein was synthesized by Genescript and cloned into EGFP-N2 vector (Clontech) to obtain MS2-EGFP fusion plasmid.

### *Construction of dual sgRNA expression vector*

42230 vector obtained from Addgene was modified for Cas9 expression and dual sgRNA expression as follows: sgRNA targeting donor sgRNA site was designed,

synthesized, annealed and inserted into 42230 vector via BbsI digestion. Then sgRNA expression cassette (BbsI) was amplified and inserted into 42230-donor sgRNA vector via NotI digestion to obtain 42230-dual sgRNA vector. In subsequent experiments, sgRNA targeting specific genome site was inserted into 42230-dual sgRNA vector via BbsI digestion. All endonucleases were purchased from NEB. Detailed information for all sgRNAs is listed in Table S2.

#### *Cell culture and plasmid transfection*

HEK 293T cells were cultured in DMEM medium (Life technologies) containing 10% FBS (Gibco) and 1% Penicillin-Streptomycin antibiotics (Life technologies) in 37°C incubator with 5% CO<sub>2</sub>. Cells were plated at a density of  $4 \times 10^5$  cells/well in a 6-well plate 24 hours prior to plasmid transfection and cultured overnight. Then donor DNA plasmid (1 µg) and 42230-dual sgRNA vector (2 µg) were co-transfected into 293T cells using lipofectamine 2000 reagent (Life Technologies) according to the manufacturer's manuals and cultured for another 48 hours, Then culture medium was replaced with medium supplemented with 2 µg/ml puromycin (Calbiochem) and cultured for another 4 days. Then cells resistant to puromycin were recovered and proliferate to enough number in puromycin-free medium for another 1 week.

For the reversion of targeted insertion with Cre recombinase-induced recombination, puromycin-selected 293T cells were transfected with plasmid expressing either Cre enzyme or EGFP and cultured for another 4 days.

For RNA-IP analysis, 293T cells with targeted insertion were transfected with plasmid expressing either MS2-EGFP fusion protein or EGFP plasmid and cultured for another 4 days.

#### *RNA-IP assay*

For RNA-IP assay, 293T cells cultured in 10 cm dish were harvested by trypsinization and resuspended in 1ml freshly-prepared RIPA buffer containing protease inhibitor cocktail (Roche) and RNase inhibitor (Fermentas). Cells were incubated on ice for 20 minutes for complete lysis. 500 $\mu$ l lysis mixture was kept for mock analysis, and another 500 $\mu$ l was used for RNA-IP analysis. Then cell lysis was centrifuged at 16,000 $\times$ g at 4 $^{\circ}$ C for 10 minutes. Supernatants were collected and added into GFP-Trap\_A beads (Chromotek), a GFP-binding protein coupled to agrose beads for immunoprecipitation. After mixed on rotator for 1 hour at 4 $^{\circ}$ C and washed with dilution buffer three times, GFP-Trap\_A beads were resuspended with Trizol reagent and total RNA was isolated.

#### *Genomic DNA isolation*

Cells were digested in 200  $\mu$ l lysis buffer containing protein kinase (Millipore) at 50 $^{\circ}$ C overnight and genome DNA was isolated as follows: 200  $\mu$ l acid-pheno: chloroform (Sangon) was added and mixed thoroughly. After centrifuging for 5 minutes at 12000 rpm. Then supernatant was absorbed and mixed with 400  $\mu$ l ethanol for DNA precipitation. After centrifuging for 5 minutes at 12000 rpm, supernatant was discarded and washed with 75% ethanol. Then after centrifugation, precipitated

DNA was dissolved with ddH<sub>2</sub>O for subsequent analysis. Primers used for PCR analysis are listed in Table S2.

*RNA purification, reverse transcription and real-time PCR*

Total RNA was isolated using Trizol reagent (Invitrogen) according to the manufacturer's manual. Then cDNA was produced from 200 ng to 1 µg purified RNA via reverse transcription using PrimeScript<sup>®</sup> RT Master Mix (Takara). Quantitative real-time PCR was performed in Rotor-Gene Q machine (Qiagen) using SYBR Green Realtime PCR Master Mix (Toyobo). Experiments were performed in biological triplicates. GAPDH was used as internal control. All qPCR primers are listed in Table S2.

*Statistical analysis*

Statistical significance based on student's t test analysis was performed with Prism 5.01 (GraphPad Software)

**Table S1. Summary of targeted insertion inside transcriptional termination of lncRNAs using CRISPR/Cas9 technology**

| targeted lncRNAs | Clone numer | Right direction | efficiency |
|------------------|-------------|-----------------|------------|
| ZEB1-AS1         | 2           | 2               | 100%       |
| PTENP1           | 2           | 2               | 100%       |
| DICER1-AS1       | 2           | 2               | 100%       |
| TUG1             | 3           | 2               | 66.6%      |
| HOTAIR           | 5           | 3               | 60%        |
| MIAT             | 4           | 2               | 50%        |

**Table S2. sgRNAs used in this study**

| sgRNAs targeting N-terminus of lncRNAs |                      |
|--|----------------------|
| ZEB1-AS1                               | GAAAATATTGATACCTGGAC |
| PTENP1                                 | ATTACTGAGTCATAGGGTAA |
| DICER1-AS1                             | GAGCACTGAGAGTGGCGAGA |
| TUG1                                   | ATGTTTATAAATGCATAGAA |
| HOTAIR                                 | ACATGTAGCTAAATAGACTC |
| MIAT                                   | TTCAACAAAGGAGCGTCACT |


|   |                      |
|---|----------------------|
| sgRNAs targeting sites after transcriptional end of lncRNAs |                      |
| ZEB1-AS1  | TAAATACAGCTAAAGAATAG |
| PTENP1  | ATCGGTGCAGCAAACCAACA |
| DICER1-AS1  | AAGCTCAAAGCGTGAAGATG |
| TUG1  | CAGTGTGAATAACTTGCCA  |
| HOTAIR  | TATGTGAAAGCAACCGACTG |
| MIAT  | AGAAGGGACGTGCTGTTTAG |
| sgRNAs targeting transcriptional start sites of lncRNAs     |                      |
| ZEB1-AS1  | AACCGAAAGAGAAAAGCGCG |
| PTENP1  | ATGAGAGACAGAGACGGCGG |
| DICER1-AS1  | CCAAAACTCCGGGCAACTG  |
| TUG1  | TTGACCATATTCCACGACCA |
| HOTAIR  | GTCCAGACCCTGTCAGCCG  |
| MIAT  | GGCTGCGGACGAGTGCGGGG |

**Table S3. qPCR and PCR primers used in this study**

|                     |                          |
|---------------------|--------------------------|
| ZEB1-AS1 QPCR for   | GCCTTCATCCCTTTAGTCCTTAGG |
| ZEB1-AS1 QPCR rev   | GTGAACAGAGTTCATTGTTTAGGG |
| PTENP1 QPCR for     | CGAATAGGTATGTCATCAGAGATC |
| PTENP1 QPCR rev     | CCAGTTTTTTCACATCCTCTCC   |
| DICER1-AS1 QPCR for | GCTTAGCTCGGACAAGGAGATG   |
| DICER1-AS1 QPCR rev | GGTGTCTGTACATCCAGACCA    |
| TUG1 QPCR for       | GCTAGAGGTCATGGTCACTG     |
| TUG1 QPCR rev       | CTGAACCACACCTTAACCTATCC  |
| HOTAIR QPCR for     | CCCAGCTTGGGACAAAAGTTG    |
| HOTAIR QPCR rev     | GGAGGAAGTTCAGGCATTGGG    |
| MIAT QPCR for       | GCTTCTCAGTGTGGTTGTGAACG  |
| MIAT QPCR rev       | GAGGGGAAAGGGTCACTGTGG    |
| ZEB1 QPCR for       | GTGGAAAGCGCTTCTCACAC     |
| ZEB1 QPCR rev       | CTCTCTCTCTCGTCCGAGTC     |
| PTENP1-AS1 QPCR for | GTTCATGACTCCTCCTATACC    |
| PTENP1-AS1 QPCR rev | GAAGGGAGAGCTTTATTCTC     |
| PTEN QPCR for       | GTAGAGGAGCCGTCAAATCC     |
| PTEN QPCR rev       | CTCTGGATCAGAGTCAGTGG     |
| DICER1 QPCR for     | GAGCTTAGGAGATCTGAGGAGG   |
| DICER1 QPCR rev     | GTACACCTGCCAGACTGTCTC    |
| MORC2 QPCR for      | CTGTGCAATTCCTACCAGAGC    |
| MORC2 QPCR rev      | GGTGATGAGGTCTCAATGTAG    |
| HOXC11 QPCR for     | CAAGAAGCGCTGCCCTTATTC    |
| HOXC11 QPCR rev     | GCCGGTCTCTGCTCAGTTTC     |

**Primers used for PCR in this study**

|                       |                          |
|-----------------------|--------------------------|
| Universal rev primer: | GGCCGTCGACAGCGTAATCTG    |
| ZEB1-AS1 end for      | GCCTTCATCCCTTTAGTCCTTAGG |
| PTENP1 end for        | GCCCTCATGTCCTAATGTGCAG   |
| DICER1-AS1 end for    | GCTTAGCTCGGACAAGGAGATG   |
| TUG1 end for          | GCTAGAGGTCATGGTCACTG     |
| HOTAIR end for        | CCCCAGCTTGGGACAAAAGTTG   |
| MIAT end for          | GCTGTGCTGGTGTAATGGTGAC   |
| ZEB1-AS1 start for    | CGTCTCTCCAAACTGGAAAAGGC  |
| PTENP1 start for      | CCTCTCAGAAGCTGCAGCCG     |
| DICER1-AS1 start for  | CCTGGCGGTGAAAGGTTAATCC   |
| TUG1 start for        | GGTTAACAACAGTCCCCTGCTTG  |
| HOTAIR start for      | GAAAAACTCTCGCTCCAGTTCCC  |
| MIAT start for        | GCTTTCCTGGCCAGGACTCTG    |




**Fig S1.** Schematics for Donor DNA plasmids.

(A-B) donor DNA plasmids for targeted insertion near transcriptional termination sites containing either 4xMS2 tags (A) or 24xMS2 tags (B). (C) donor DNA plasmid for targeted insertion near transcriptional start sites containing 4xMS2 tags. Detailed plasmid sequences were provided in appendix.

| LncRNA specific sgRNA sequences |  | Targeted donor sequence        |
|---------------------------------|--|--------------------------------|
| <b>sgRNA PAM</b>                |  |                                |
| ZEB1-AS1 sgRNA                  | GAAAATATTGATACCTGGACTGG                | GGCCAGTACCCAAAAAGCGGGGGGGCGCGC |
| Targeted clone1                 | GAAAATATTGATACCTG-----                 | -----CGGGGGGGCGCGC             |
| Targeted clone2                 | GAAAATATTGATACCTGG      63bp insertion | GCGGGGGGGCGCGC                 |
| PTENP1 sgRNA                    | CCCTTACCCTATGACTCAGTAAT                | GGCCAGTACCCAAAAAGCGGGGGGGCGCGC |
| Targeted clone                  | CCCTTA-----                            | -----CGGGGGGGCGCGC             |
| DICER1-AS1 sgRNA                | GAGCACTGAGAGTGGCGAGAAGG                | GGCCAGTACCCAAAAAGCGGGGGGGCGCGC |
| Targeted clone                  | GAGCACTGAGAGTGGCG-----                 | -----CGGGGGGGCGCGC             |
| TUG1 sgRNA                      | ATGTTTATAAATGCATAGAAAGG                | GGCCAGTACCCAAAAAGCGGGGGGGCGCGC |
| Targeted clone                  | ATGTTTATAAATGCATA-----                 | -----CGGGGGGGCGCGC             |
| HOTAIR sgRNA                    | ACATGTAGCTAAATAGACTCAGG                | GGCCAGTACCCAAAAAGCGGGGGGGCGCGC |
| Targeted clone                  | ACATGTAGCTAAATAGA-----                 | -----CGGGGGGGCGCGC             |
| MIAT1 sgRNA                     | TTCAACAAAGGAGCGTCACTTGG                | GGCCAGTACCCAAAAAGCGGGGGGGCGCGC |
| Targeted clone                  | TTCAACAAAGGAGCGTCA-----                | -----CGGGGGGGCGCGC             |


**Fig S2.** Detailed sequences surrounding fusion sites of six lncRNAs with targeted insertion inside transcriptional termination.



**Fig S3.** LncRNA stimulation by CRISPR/Cas9-mediated targeted insertion after transcriptional termination.

(A) A scheme for CRISPR/Cas9-mediated targeted insertion after transcriptional termination site similar to Fig. 1A. (B) PCR analysis of targeted integration for six different lncRNAs using genomic DNA of 293T cells with established targeted insertion. (C) Quantitative PCR analysis of targeted lncRNA expression in 293T cells with established targeted insertion. (D) Quantitative PCR analysis of neighboring genes of targeted lncRNA expression in 293T cells with established targeted insertion. 293T cells without treatment were used as negative control and GAPDH was used as internal control in (C) and (D) analysis. All experiments were performed independently three times and one representative result was shown.  $***P < 0.005$

(two-sided Student's *t*-test)



**Fig S4.** LncRNA manipulation by CRISPR/Cas9-mediated targeted insertion near transcriptional start site.

(A) Schematics of CRISPR/Cas9-mediated targeted insertion near transcriptional start site of lncRNAs. Circular modified gene trap vector is initially linearized by

vector-targeting Cas9-sgRNA complex. Simultaneously double strand breaks (DSBs) are induced inside transcriptional termination site by genome-targeting Cas9-sgRNA complex. After transfecting Cre expression vector, established targeted insertion could be depleted. (B) PCR analysis of targeted integration for six different lncRNAs using genomic DNA of 293T cells with established targeted insertion. (C) Quantitative PCR analysis of targeted lncRNA expression in 293T cells with established targeted insertion. (D) Quantitative PCR analysis of neighboring gene's expression in 293T cells with established targeted insertion. (E) Quantitative PCR analysis of targeted lncRNA expression in 293T cells with established targeted insertion transfected with Cre expression vector. (F) Quantitative PCR analysis of neighboring gene's expression in 293T cells with established targeted insertion transfected with Cre expression vector. GAPDH was used as internal control in (C-F) analysis. All experiments were performed independently three times and one representative result was shown. \*\* $P < 0.01$ , \* $P < 0.005$  (two-sided Student's *t*-test)

## Appendix

### Detailed plasmid sequences and information

#### CMV-Puro-MS2 tag plasmid

CMV promoter

Puromycin

LoxP

4XMS2

sgRNA

TCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCG  
GAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCC  
GTCAGGGCGCGTCAGCGGGTGTGGCGGGTGTCCGGGGCTGGCTTAACTAT  
GCGGCATCAGAGCAGATTGTAAGTGTGAGAGTGCACCATAATATGGAGTTCCG  
CGTTACATAACTTACGGTAAATGGCCCCGCTGGCTGACCGCCCAACGACC  
CCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATA  
GGGACTTTCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCA  
CTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGT  
CAATGACGGTAAATGGCCCCGCTGGCATTATGCCCAGTACATGACCTTAT  
GGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCA  
TGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGAC  
TCACGGGGATTTCCAAGTCTCCACCCATTGACGTCAATGGGAGTTTGTTT  
TGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACCTCCGCCCC  
ATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCA  
GAGCTGGTTTAGTGAACCGTCAGATCCGCTAGGATCCCATGACCGAGTAC  
AAGCCACGGTGCGCCTCGCCACCCGCGACGACGTCCCAGGGCCGTACG  
CACCTCGCCGCCGCGTTCGCCGACTACCCCGCCACGCGCCACACCGTCCG  
ATCCGGACCGCCACATCGAGCGGGTCACCGAGCTGCAAGAACTCTTCCTC  
ACGCGCGTCGGGCTCGACATCGGCAAGGTGTGGGTTCGCGGACGACGGCG  
CCGCCGTGGCGGTCTGGACCACGCCGAGAGCGTCGAAGCGGGGGCGGT  
GTTCCGCCGAGATCGGCCCGCGCATGGCCGAGTTGAGCGGTTCCCGGCTGG  
CCGCGCAGCAACAGATGGAAGGCCTCCTGGCGCCGACCGGCCCAAGGA  
GCCCCGTGGTTCCTGGCCACCGTCGGAGTCTCGCCCGACCACCAGGGCA  
AGGGTCTGGGCAGCGCCGTCGTGCTCCCCGGAGTGGAGGCGGCCGAGCGC  
GCCGGGGTGCCCGCCTTCCTGGAAACCTCCGCGCCCCGCAACCTCCCCTTC  
TACGAGCGGCTCGGCTTACCCTCACCGCCGACGTCGAGGTGCCCGAAGG  
ACCGCGCACCTGGTGCATGACCCGCAAGCCCGGTGCCTGACAGATCTTAG  
ATTATGATAAATTCGTATAGCATAACATTATACGAAGTTATTTACCGGTCG  
GGAATTCGGCCAGTACCCAAAAAGCGGGGGGGCGCGCCGGGGTCTGGTG  
GCAGTGGAGGGGGGTCTTACCATAACGATGTTCCAGATTACGCTTGATTA  
CCCCTATGATGTGCCTGACTACGCATGATTACCATAACGATGTTCCAGATT  
ACGCTGTTCGACGGCCAACATGAGGATCACCCATGTCTGCAGGGCCTTTTT  
GGCCAACATGAGGATCACCCATGTCTGCAGGGCCTTTTTGGCCAACATGA  
GGATCACCCATGTCTGCAGGGCCTTTTTGGCCAACATGAGGATCACCCAT  
GTCTGCAGGGCCGCGCCATAAATTCGTATAGCATAACATTATACGAAGTTA  
TCGGGATCCATGATATCGCTAGCAAGCTTGCGGCCGCTTCCTCGCTCACTG

ACTCGCTGCGCTCGGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCA  
AAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGA  
ACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGC  
GTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCACAAAA  
TCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATAC  
CAGGCGTTTTCCCCTGGAAGCTCCCTCGTGCCTCTCCTGTTCCGACCCTG  
CCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTT  
TCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTGTTCCGCTCC  
AAGCTGGGCTGTGTGCACGAACCCCCGTTACGCCGACCGCTGCGCCTT  
ATCCGGTAACACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGC  
CACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGG  
CGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAA  
GAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAA  
AGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGG  
TTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAG  
AAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGAACGAAAAC  
CACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAG  
ATCCTTTTAAATTA AAAATGAAGTTTTAAATCAATCTAAAGTATATATGAG  
TAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCA  
GCGATCTGTCTATTTTCGTTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAG  
ATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGAT  
ACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCCAGC  
CAGCCGGAAGGGCCGAGCGCAGAAGTGGTCTTCAACTTTATCCGCCTCC  
ATCCAGTCTATTAATTGTTGCCGGAAGCTAGAGTAAGTAGTTCGCCAGTT  
AATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTACGC  
TCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGA  
GTTACATGATCCCCATGTTGTGCAAAAAGCGGTTAGCTCCTTCGGTCCT  
CCGATCGTTGTCAGAAGTAAGTTGGCCGAGTGTTATCACTCATGGTTATG  
GCAGCACTGCATAATTCTTTACTGTCATGCCATCCGTAAGATGCTTTTCT  
GTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCG  
ACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATA  
GCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAA  
CTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGT  
GCACCCAAGTATCTTCAGCATCTTTTACTTTTACCAGCGTTTCTGGGTGA  
GCAAAAACAGGAAGGCAAAATGCCGCAAAAAGGGAATAAGGGCGACA  
CGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATT  
ATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAA  
ATAAACAAATAGGGGTTCCGCGCACATTTCCCGAAAAGTGCCACCTGAC  
GTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTAT  
CACGAGGCCCTTTCGTC

**CMV-Puro-24XMS2 tag plasmid**

CMV promoter

Puromycin

LoxP

24XMS2

sgRNA

tcgcgctttcggatgacgggtgaaaaccttgacacatgcagctccccggagacggtcacagcttgtctgtaagcggatg  
ccgggagcagacaagcccgtcagggcgcgtcagcgggtgttggcgggtgtcggggctggcttaactatgcggcatcag  
agcagattgtactgagagtgcaccataatATGGAGTTCCGCGTTACATAACTTACGGTAAAT  
GGCCCGCCTGGCTGACCGCCCAACGACCCCGCCATTGACGTCAATAAT  
GACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAAT  
GGGTGGAGTATTTACGGTAAACTGCCACTTGGCAGTACATCAAGTGTAT  
CATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGC  
CTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTA  
CATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTA  
CATCAATGGGCGTGGATAGCGGTTTACTCACGGGGATTCCAAGTCTCC  
ACCCATTGACGTCAATGGGAGTTTGTGGTGGCACCAAAATCAACGGGAC  
TTCCAAAATGTCGTAACAACCTCCGCCCATGACGCAAAATGGGCGGTAG  
GCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTGGTTTTAGTGAACCGTC  
AGATCCGCTAGGATCCCatgaccgagtacaagcccacgggtgcgctcgcaccgcgacgacgtccca  
gggcccgtacgaccctcgcgcccgttcgcccactaccccgccacgcgccacaccgtcgtcggaccgcccacatcg  
agcgggtcaccgagctgcaagaactcttctcaecgcgctcgggtcgcacatcggcaaggtgtgggtcgggacgacg  
gcccgcctgtggcggtctgaccacgccggagagcgtcgaagcggggcggtgttcgccgagatcggcccgcgatg  
gcccagittgagcggttcccggctgcccgcgagcaacagatggaagcctcctggcggcaccgcccgaaggagcc  
cgcgtggttctggccaccgtcggagctcgcggaccaccaggggcaagggctcgggcagcgcgctcgtctcccgg  
agtggaggcggccgagcgcgcccgggtgcccgccttctggaaacctccgcgccccgcaacctccccttctacgagcg  
gctcggcttaccgtcaccgcccagctcaggggtcccgaaggaccgcgacctggtgatgaccgcaagcccgggtc  
ctgacagatcttagatTATGATAACTTCGTATAGCATAACATTATACGAAGTTATTTTA  
CCGGTCGGGAATTCGGCCAGTACCCAAAAGCGGGGGGGCGCGCCGGGG  
TCTGGTGGCAGTGGAGGGGGTCTACCCATACGATGTTCCAGATTACGC  
TTGATTACCCCTATGATGTGCCTGACTACGCATGATTACCCATACGATGTT  
CCAGATTACGCTGtcgacaactagtTACGGTACTTATTGCCAAGAAAGCACGAGC  
ATCAGCCGTGCCTCCAGGTTCGAATCTTCAAACGACGACGATCACGCGTCG  
CTCCAGTATTCCAGGGTTCATCAGATCCTACGGTACTTATTGCCAAGAAAG  
CACGAGCATCAGCCGTGCCTCCAGGTTCGAATCTTCAAACGACGACGATCA  
CGCGTCGCTCCAGTATTCCAGGGTTCATCAGATCCTACGGTACTTATTGCC  
AAGAAAGCACGAGCATCAGCCGTGCCTCCAGGTTCGAATCTTCAAACGACG  
ACGATCACGCGTCGCTCCAGTATTCCAGGGTTCATCAGATCCTACGGTACT  
TATTGCCAAGAAAGCACGAGCATCAGCCGTGCCTCCAGGTTCGAATCTTCA  
AACGACGACGATCACGCGTCGCTCCAGTATTCCAGGGTTCATCAGATCCT  
ACGGTACTTATTGCCAAGAAAGCACGAGCATCAGCCGTGCCTCCAGGTTCG  
AATCTTCAAACGACGACGATCACGCGTCGCTCCAGTATTCCAGGGTTCAT  
CAGATCCTACGGTACTTATTGCCAAGAAAGCACGAGCATCAGCCGTGCCT  
CCAGGTTCGAATCTTCAAACGACGACGATCACGCGTCGCTCCAGTATTCCA  
GGGTTTCATCgtcgacactagtTACGGTACTTATTGCCAAGAAAGCACGAGCATCA  
GCCGTGCCTCCAGGTTCGAATCTTCAAACGACGACGATCACGCGTCGCTCC  
AGTATTCCAGGGTTCATCAGATCCTACGGTACTTATTGCCAAGAAAGCAC

GAGCATCAGCCGTGCCTCCAGGTTCGAATCTTCAAACGACGACGATCACGC  
GTCGCTCCAGTATTCCAGGGTTCATCAGATCCTACGGTACTTATTGCCAAG  
AAAGCACGAGCATCAGCCGTGCCTCCAGGTTCGAATCTTCAAACGACGACG  
ATCACGCGTCGCTCCAGTATTCCAGGGTTCATCAGATCCTACGGTACTTAT  
TGCCAAGAAAGCACGAGCATCAGCCGTGCCTCCAGGTTCGAATCTTCAAAC  
GACGACGATCACGCGTCGCTCCAGTATTCCAGGGTTCATCAGATCCTACG  
GTACTTATTGCCAAGAAAGCACGAGCATCAGCCGTGCCTCCAGGTTCGAAT  
CTTCAAACGACGACGATCACGCGTCGCTCCAGTATTCCAGGGTTCATCAG  
ATCCTACGGTACTTATTGCCAAGAAAGCACGAGCATCAGCCGTGCCTCCA  
GGTCGAATCTTCAAACGACGACGATCACGCGTCGCTCCAGTATTCCAGGG  
TTCATCgTCGACGGCCAACATGAGGATCACCCATGTCTGCAGGGCCTTTTT  
GGCCAACATGAGGATCACCCATGTCTGCAGGGCCTTTTTGGCCAACATGA  
GGATCACCCATGTCTGCAGGGCCTTTTTGGCCAACATGAGGATCACCCAT  
GTCTGCAGGGCCGCGCCATAACTTCGTATAGCATAACATTATACGAAGTTA  
TCGGGATCCATGATATCGCTAGCAAGCTTGCGGCCgcttcctcgtcactgactcgtcgc  
ctcggctgcttgcggtcgcggcgagcggatcagctcactcaaaaggcggtaatacggttatccacagaatcaggggataacg  
caggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgctgtgctggcgttttccatag  
gctccgccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaccgacaggactataaagatac  
caggcggttccccctggaagtcctcgtgctcctcgttccgaccctgcccgttaccggatacctgcccgtttctcct  
tcgggaagcgtggcgtttctcatagctcagctgtaggtatctcagttcggtaggtcgttcgctccaagctgggctgtgt  
gcacgaacccccgttcagcccaccgctgcgccttatccggaactatcgtcttgagccaaccggtaagacacgactt  
atgccactggcagcagccactggtaacaggattagcagagcaggtatgtaggcgggtgtacagagttctgaagtggt  
ggcctaactacggctacactagaagaacagtatttggatctgcgctcgtcgaagccagttacctcggaaaaagagttggt  
agctcttgatccggcaaacaaaccaccgctggtagcgggtggtttttggttcaagcagcagattacgcgcaaaaaaag  
gatctcaagaagatccttgatctttctacggggtctgacgctcagtggaacgaaaactcacgttaagggattttggtcatga  
gattatcaaaaaggatcttcacctagatccttttaataaaatgaagtttaatacaatctaaagtatatatgagtaacttggt  
ctgacagttaccaatgcttaacagtgaggcacctatctcagcagatctgtctatttcggtcatcatagttgcctgactccccgctc  
gtgtagataactacgatacgggagggcttaccatctgccccagtgctgcaatgataccgcgagaccacgctcaccggc  
tccagattatcagcaataaaccagccagccggaagggccgagcgcagaagtggtcctgcaactttatccgctccatcca  
gtctattaattgttgcgggaagctagagtaagtagttcgccagttatagtttgcgcaacggtgttccattgctacaggtc  
gtggtgtcacgctcgtggttggatggcttcaatcagctccggttccaacgatcaaggcagttacatgatccccatggtg  
tgcaaaaaagcggtagctcctcgtcctccgatcgttgcagaagtaagttggccgagtggtatcactcatggttatggca  
gcaactgcataattcttactgtcatgccatccgtaagatgctttctgtgactggtgagtagtcaaccaagtcattctgagaata  
gtgatgcggcgaccgagttgctcttggccggcgtcaatacgggataataaccgcccacatagcagaactttaaaagtgt  
catcattggaaaacgttctcggggcgaactctcaaggatctaccgctgttgagatccagttcagatgtaaccactcgtg  
caccactgatcttcagcatctttactttaccagcgtttctgggtgagcaaaaacaggaaggcaaaaatgccgcaaaaa  
gggaataagggcgacacggaaatgttgaatactcactcttctttcaatattattgaagcatttatcaggggttattgtctcat  
gagcggatacatattgaatgtatttagaaaaataaacaatagggggtccgcgcacatttccccgaaaagtgccacctgac  
gtctaagaaccattatcatgacattaacctataaaaataggcgtatcacgagcccttctc

MS2 tag-Puro-polyA

Puromycin

LoxP

4XMS2

sgRNA

polyA

TCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCG  
GAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCC  
GTCAGGGCGCGTCAGCGGGTGTGGCGGGTGTTCGGGGCTGGCTTAACTAT  
GCCGCATCAGAGCAGATTGTAAGTGCACCATATGATAACTTCGTA  
TAGCATAACATTATACGAAGTTATTTTACCGGTCGGGAATTCGGCCAGTACC  
CAAAAAGCGGGGGGGCGCGCCGGGGTCTGGTGGCAGTGGAGGGGGGTCC  
TACCATAACGATGTTCCAGATTACGCTTGATTACCCCTATGATGTGCCTGA  
CTACGCATGATTACCCATAACGATGTTCCAGATTACGCTGTCGACGGCCAA  
CATGAGGATCACCCATGTCTGCAGGGCCTTTTTGGCCAACATGAGGATCA  
CCCATGTCTGCAGGGCCTTTTTGGCCAACATGAGGATCACCCATGTCTGCA  
GGGCCTTTTTGGCCAACATGAGGATCACCCATGTCTGCAGGGCCGCGCCA  
TAACTTCGTATAGCATAACATTATACGAAGTTATCGGGATCCCATGACCGA  
GTACAAGCCACGGTGCGCCTCGCCACCCGCGACGACGTCCCAGGGCCG  
TACGCACCCTCGCCGCGCGTTTCGCCGACTACCCCGCCACGCGCCACACC  
GTCGATCCGGACCGCCACATCGAGCGGGTCACCGAGCTGCAAGAACTCTT  
CCTCACGCGCGTCCGGCTCGACATCGGCAAGGTGTGGGTGCGGGACGACG  
GCGCCGCGTGGCGGTCTGGACCACGCCGGAGAGCGTCGAAGCGGGGGC  
GGTGTTCGCCGAGATCGGCCCGCGCATGGCCGAGTTGAGCGGTTCCCGGC  
TGGCCGCGCAGCAACAGATGGAAGGCCTCCTGGCGCCGACCCGGCCCAA  
GGAGCCCGCGTGGTTCCTGGCCACCGTCGGAGTCTCGCCCGACCACCAGG  
GCAAGGGTCTGGGCAGCGCCGTCGTGCTCCCGGAGTGGAGGCGGCCGA  
GCGCGCCGGGGTGCCCGCCTTCTGGAAACCTCCGCGCCCCGCAACCTCC  
CCTTCTACGAGCGGCTCGGCTTACCGTACCCGCCGACGTCGAGGTGCC  
GAAGGACCGCGCACCTGGTGCATGACCCGCAAGCCCGGTGCCTGACAGAT  
CTTAGCCGCGGCCGCACAACTTGTTTATTGCAGCTTATAATGGTTACAAAT  
AAAGCAATAGCATCACAAATTCACAAATAAAGCATTTTTTTCACTGCATT  
CTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTAGCTCTTCCGCTTCCT  
CGCTCACTGACTCGCTGCGCTCGGTCTGTTCCGGCTGCGGCGAGCGGTATCA  
GCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGC  
AGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAA  
AAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCAT  
CACAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTAT  
AAAGATAACAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCCTCTCCTGTTT  
CGACCCTGCCGCTTACCGGATACTGTCCGCTTTCTCCCTTCGGGAAGCG  
TGCGCTTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCG  
TTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCGTTTCAGCCCGACCGCT  
GCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGAC  
TTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTA  
TGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACA  
CTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCG

GAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGC  
GGTGGTTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATC  
TCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGA  
AAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCA  
CCTAGATCCTTTTAAATTA AAAATGAAGTTTTAAATCAATCTAAAGTATAT  
ATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCT  
ATCTCAGCGATCTGTCTATTTTCGTTCCATAGTTGCCTGACTCCCCGTC  
GTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGC  
AATGATACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAA  
ACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCC  
GCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCCG  
CCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTG  
TCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCA  
AGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTT  
CGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCAT  
GGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATG  
CTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTAT  
GCGGCGACCGAGTTGCTCTTGCCCCGGCGTCAATACGGGATAATACCGCGC  
CACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGG  
CGAAAACCTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACC  
CACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTTACCAGCGTTTCT  
GGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAGGGAATAAGG  
GCGACACGGAAATGTTGAATACTCATACTCTTCTTTTCAATATTATTGA  
AGCATTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATT  
TAGAAAAATAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCC  
ACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATA  
GGCGTATCACGAGGCCCTTTCGTC